2023
Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial
Grilo C, Lydecker J, Jastreboff A, Pittman B, McKee S. Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial. Obesity 2023, 31: 2762-2773. PMID: 37751990, PMCID: PMC10600891, DOI: 10.1002/oby.23898.Peer-Reviewed Original ResearchConceptsNaltrexone/bupropionBinge-eating disorderObesity statusLogistic regressionWeight lossPlacebo-controlled trialWeight loss outcomesPrevalent psychiatric disordersEvidence-based treatmentsPost-treatment assessmentBinge-eating frequencyGreater percentage weight lossMedication outcomesRemission ratePharmacological optionsPlaceboBupropionPsychiatric disordersPercentage weight lossMixed modelsDisordersObesityPatientsSignificant reductionWeight reduction
2012
Effects of Varenicline and Bupropion on Cognitive Processes Among Nicotine-Deprived Smokers
Ashare RL, McKee SA. Effects of Varenicline and Bupropion on Cognitive Processes Among Nicotine-Deprived Smokers. Experimental And Clinical Psychopharmacology 2012, 20: 63-70. PMID: 21942262, PMCID: PMC3640636, DOI: 10.1037/a0025594.Peer-Reviewed Original ResearchConceptsNicotine deprivationCognitive processesMeasures of attentionNicotine-deprived smokersMeasures of cravingEffects of vareniclineNegative affectOvernight abstinenceCurrent data highlightMemoryReduced accuracyDaily smokersCurrent sampleDifficulty concentratingLaboratory sessionsEffects of bupropionFuture researchReaction timeSex differencesRecent researchAbstinence ratesDeficitsNew pharmacological treatmentsParticipantsSmoking cessation
2010
Menstrual cycle phase at quit date and smoking abstinence at 6 weeks in an open label trial of bupropion
Mazure CM, Toll B, McKee SA, Wu R, O’Malley S. Menstrual cycle phase at quit date and smoking abstinence at 6 weeks in an open label trial of bupropion. Drug And Alcohol Dependence 2010, 114: 68-72. PMID: 20832955, PMCID: PMC3016455, DOI: 10.1016/j.drugalcdep.2010.07.024.Peer-Reviewed Original ResearchConceptsMenstrual cycle phaseQuit datePoint prevalence abstinencePremenopausal womenBupropion SRFollicular phaseLuteal phaseAbsence of pharmacotherapySustained release bupropionOpen-label trialCycle phaseMechanism of actionRelease bupropionLabel trialNicotine replacementCessation interventionsOpen trialTreatment completionCessation outcomesContinuous abstinenceQuit dayGonadal hormonesTreatment periodAbstinence outcomesQuit attempts
2008
Developing human laboratory models of smoking lapse behavior for medication screening
McKee SA. Developing human laboratory models of smoking lapse behavior for medication screening. Addiction Biology 2008, 14: 99-107. PMID: 18855800, PMCID: PMC2732001, DOI: 10.1111/j.1369-1600.2008.00135.x.Peer-Reviewed Original ResearchConceptsMedication screeningHuman laboratory modelSmoking behaviorMedication developmentSubsequent ad libitum smokingAd libitum smokingDrug Administration approvalSelf-administration sessionsMedication signalsCessation medicationsLapse behaviorAdministration approvalFirst cigaretteAbstinence outcomesQuit attemptsSmoking relapseUS FoodSmokingSmokersRelapseImportant targetTranslational workCigarettesScreeningMechanistic evaluationMessage Framing for Smoking Cessation: The Interaction of Risk Perceptions and Gender
Toll BA, Salovey P, O'Malley SS, Mazure CM, Latimer A, McKee SA. Message Framing for Smoking Cessation: The Interaction of Risk Perceptions and Gender. Nicotine & Tobacco Research 2008, 10: 195-200. PMID: 18188760, PMCID: PMC2527723, DOI: 10.1080/14622200701767803.Peer-Reviewed Original ResearchConceptsMessage framing interventionsRisk of cessationSmoking cessationLung cancerClinical trialsGain-framed messagesHigh riskSmoking relapseHealth message framingHealth problemsLoss-framed messagesSmokingFraming interventionCessationNumber of daysInfluence of genderInterventionRiskRisk perceptionWomenMedian splitGain-framed conditionDaysMenGender differences
2007
Subjective reactivity to the first cigarette of the day as a predictor of smoking relapse: A preliminary study
Toll BA, Schepis TS, O’Malley S, McKee SA, Krishnan-Sarin S. Subjective reactivity to the first cigarette of the day as a predictor of smoking relapse: A preliminary study. Drug And Alcohol Dependence 2007, 89: 302-305. PMID: 17320313, PMCID: PMC2475673, DOI: 10.1016/j.drugalcdep.2007.01.011.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAffectAgedAntidepressive Agents, Second-GenerationBehavior TherapyBupropionCircadian RhythmDelayed-Action PreparationsFemaleHumansMaleMiddle AgedMotivationNicotineOutcome Assessment, Health CarePrognosisSecondary PreventionSmokingSmoking CessationSubstance Withdrawal SyndromeSurveys and QuestionnairesTobacco Use DisorderConceptsFirst cigaretteSmoking relapseEnd of treatmentCessation treatment outcomeInitial cigaretteWithdrawal symptomsClinical trialsQuit dayTreatment outcomesNovel predictorRelapseCigarettesPreliminary studyTime pointsGreater decreaseCravingSubjective responsesSubjective reactivityDaysFuture studiesSignificant changesWithdrawalPredictorsResponseBupropion